Metsera

Clinical trials sponsored by Metsera, explained in plain language.

Now part of Pfizer Inc. PFE NYSE

Biotech developing obesity and metabolic disease treatments, owned by Pfizer.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.

Completed 1

New weekly shot shows promise for obesity – but It's early days

Disease control Completed

This study tests a new drug called MET097, given as a weekly injection, to see if it is safe and helps with weight loss in adults who are overweight or obese but otherwise healthy. About 120 participants will receive either MET097 or a placebo for up to 12 weeks, with some explor…

Phase 1/2 • Sponsor: Metsera, a wholly owned subsidiary of Pfizer • Aim: Disease control

Last updated Jun 27, 2026 09:00 UTC

Metsera

New weekly shot shows promise for obesity – but It's early days